Baroody F M, Assanasen P, Chung J, Naclerio R M
Section of Otolaryngology-Head and Neck Surgery, Pritzker School of Medicine, University of Chicago, Ill 60637, USA.
Arch Otolaryngol Head Neck Surg. 2000 Jun;126(6):749-54. doi: 10.1001/archotol.126.6.749.
We have previously reported that preconditioning allergic subjects with hot, humid air (HHA) (temperature, 37 degrees C; relative humidity >95%) in an environmental chamber resulted in partial inhibition of the early response to nasal allergen challenge.
To investigate whether this inhibitory effect could be achieved by inhalation of HHA via a face mask.
Randomized, 4-way crossover study.
Eighteen subjects with seasonal allergic rhinitis participated in the study outside of their allergy season.
Subjects underwent preconditioning with room air (RA) (temperature, 25 degrees C; relative humidity <20%) or HHA either in a chamber or delivered via a face mask for 1 hour prior to and during nasal challenge with diluent for the allergen extract followed by 2 increasing doses of allergen.
Net changes from diluent challenge for all parameters were compared between HHA and RA in each delivery method. Hot, humid air delivered by mask significantly inhibited the mean+/-SEM number of allergen-induced sneezes (HHA, 2.7+/-0.6; RA, 6.6+/-2.1; P=.03), congestion score (HHA, 2.3+/-0.5; RA, 3.4+/-0.5; P=.01), and secretion weights (HHA, 26.9+/-4.4 mg; RA, 38.6+/-5.0 mg; P=.048). However, HHA inhaled in a chamber significantly inhibited only the mean+/-SEM allergen-induced congestion (HHA, 1.2+/-0.4; RA, 3.6+/-0.6; P=.002) and pruritus (HHA, 0.7+/-0.3; RA, 2.3+/-0.5; P=.002) scores.
Preconditioning the nasal mucosa with HHA partially decreases the early response to nasal challenge with antigen irrespective of the administration technique. The secretory response, however, is only inhibited by localized delivery of HHA to the nose. The inhibitory effects of HHA are therefore probably related to local changes in the nasal mucosa and are not dependent on total body exposure to HHA.
我们之前报道过，在环境舱中用热湿空气（HHA）（温度37摄氏度；相对湿度>95%）对过敏受试者进行预处理，可部分抑制鼻过敏原激发试验的早期反应。
研究通过面罩吸入HHA是否能达到这种抑制效果。
随机、四交叉研究。
18名季节性变应性鼻炎患者在过敏季节之外参与了本研究。
在使用过敏原提取物稀释液进行鼻腔激发试验之前及试验过程中，受试者在环境舱中或通过面罩接受常空气（RA）（温度25摄氏度；相对湿度<20%）或HHA预处理1小时，随后给予2次递增剂量的过敏原。
比较了每种给药方式下HHA和RA之间所有参数相对于稀释液激发试验的净变化。面罩输送的热湿空气显著抑制了过敏原诱发的喷嚏平均次数±标准误（HHA，2.7±0.6；RA，6.6±2.1；P = 0.03）、充血评分（HHA，2.3±0.5；RA，3.4±0.5；P = 0.01）和分泌物重量（HHA，26.9±4.4毫克；RA，38.6±5.0毫克；P = 0.048）。然而，在环境舱中吸入的HHA仅显著抑制了过敏原诱发的平均充血±标准误（HHA，1.2±0.4；RA，3.6±0.6；P = 0.002）和瘙痒（HHA，0.7±0.3；RA，2.3±0.5；P = 0.002）评分。
无论给药技术如何，用HHA预处理鼻黏膜可部分降低对抗原鼻腔激发试验的早期反应。然而，分泌反应仅通过将HHA局部输送到鼻部而受到抑制。因此，HHA的抑制作用可能与鼻黏膜的局部变化有关，而不依赖于全身暴露于HHA。
